These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 29954938)

  • 1. Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.
    Ruiz-Heredia Y; Sánchez-Vega B; Onecha E; Barrio S; Alonso R; Martínez-Ávila JC; Cuenca I; Agirre X; Braggio E; Hernández MT; Martínez R; Rosiñol L; Gutierrez N; Martin-Ramos M; Ocio EM; Echeveste MA; de Oteyza JP; Oriol A; Bargay J; Gironella M; Ayala R; Bladé J; Mateos MV; Kortum KM; Stewart K; García-Sanz R; Miguel JS; Lahuerta JJ; Martinez-Lopez J
    Haematologica; 2018 Nov; 103(11):e544-e548. PubMed ID: 29954938
    [No Abstract]   [Full Text] [Related]  

  • 2. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.
    Weißbach S; Langer C; Puppe B; Nedeva T; Bach E; Kull M; Bargou R; Einsele H; Rosenwald A; Knop S; Leich E
    Br J Haematol; 2015 Apr; 169(1):57-70. PubMed ID: 25521164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
    Walker BA; Boyle EM; Wardell CP; Murison A; Begum DB; Dahir NM; Proszek PZ; Johnson DC; Kaiser MF; Melchor L; Aronson LI; Scales M; Pawlyn C; Mirabella F; Jones JR; Brioli A; Mikulasova A; Cairns DA; Gregory WM; Quartilho A; Drayson MT; Russell N; Cook G; Jackson GH; Leleu X; Davies FE; Morgan GJ
    J Clin Oncol; 2015 Nov; 33(33):3911-20. PubMed ID: 26282654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.
    van de Donk NWCJ; Casneuf T; Di Cara A; Parren PW; Zweegman S; van Kessel B; Lokhorst HM; Usmani SZ; Lonial S; Richardson PG; Chiu C; Mutis T; Nijhof IS; Sasser AK
    Br J Haematol; 2019 Feb; 184(3):475-479. PubMed ID: 29411874
    [No Abstract]   [Full Text] [Related]  

  • 5. Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients.
    Macauda A; Castelli E; Buda G; Pelosini M; Butrym A; Watek M; Kruszewski M; Vangsted AJ; Rymko M; Jamroziak K; Abildgaard N; Haastrup EK; Mazur G; Ríos R; Jurczyszyn A; Zawirska D; Dudziński M; Raźny M; Dutka M; Tomczak W; Suska A; Druzd-Sitek A; Marques H; Petrini M; Markiewicz M; Martinez-Lopez J; Ebbesen LH; Iskierka-Jażdżewska E; Sainz J; Canzian F; Campa D
    Br J Haematol; 2018 Nov; 183(3):375-384. PubMed ID: 30079960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
    Jiménez C; Jara-Acevedo M; Corchete LA; Castillo D; Ordóñez GR; Sarasquete ME; Puig N; Martínez-López J; Prieto-Conde MI; García-Álvarez M; Chillón MC; Balanzategui A; Alcoceba M; Oriol A; Rosiñol L; Palomera L; Teruel AI; Lahuerta JJ; Bladé J; Mateos MV; Orfão A; San Miguel JF; González M; Gutiérrez NC; García-Sanz R
    J Mol Diagn; 2017 Jan; 19(1):99-106. PubMed ID: 27863261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.
    Martinez-Lopez J; Sanchez-Vega B; Barrio S; Cuenca I; Ruiz-Heredia Y; Alonso R; Rapado I; Marin C; Cedena MT; Paiva B; Puig N; Mateos MV; Ayala R; Hernández MT; Jimenez C; Rosiñol L; Martínez R; Teruel AI; Gutiérrez N; Martin-Ramos ML; Oriol A; Bargay J; Bladé J; San-Miguel J; Garcia-Sanz R; Lahuerta JJ
    Leukemia; 2017 Jun; 31(6):1446-1449. PubMed ID: 28210002
    [No Abstract]   [Full Text] [Related]  

  • 8. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
    Agnarelli A; Chevassut T; Mancini EJ
    Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.
    Kortuem KM; Braggio E; Bruins L; Barrio S; Shi CS; Zhu YX; Tibes R; Viswanatha D; Votruba P; Ahmann G; Fonseca R; Jedlowski P; Schlam I; Kumar S; Bergsagel PL; Stewart AK
    Blood Cancer J; 2016 Feb; 6(2):e397. PubMed ID: 26918361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.
    Lazareth A; Song XY; Coquin A; Harel S; Karlin L; Belhadj K; Roos-Weil D; Frenzel L; Tamburini J; Macro M; Chevret S; Loiseau HA; Minvielle S; Fermand JP; Soulier J; Bories JC; Arnulf B
    Haematologica; 2015 Nov; 100(11):e471-4. PubMed ID: 26206803
    [No Abstract]   [Full Text] [Related]  

  • 11. Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy.
    Brioli A; Boyd KD; Kaiser MF; Pawlyn C; Wu P; Gregory WM; Owen R; Ross FM; Jackson GH; Cavo M; Davies FE; Morgan GJ
    Br J Haematol; 2013 Apr; 161(2):291-4. PubMed ID: 23356460
    [No Abstract]   [Full Text] [Related]  

  • 12. Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients.
    Austen B; Barone G; Reiman A; Byrd PJ; Baker C; Starczynski J; Nobbs MC; Murphy RP; Enright H; Chaila E; Quinn J; Stankovic T; Pratt G; Taylor AM
    Br J Haematol; 2008 Sep; 142(6):925-33. PubMed ID: 18573109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.
    Chen L; Fan F; Deng J; Xu J; Xu A; Sun C; Hu Y
    Ann Hematol; 2019 Apr; 98(4):963-970. PubMed ID: 30610280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [[Gene expression of key enzymes for all-trans- retinoic acid biosynthesis - ALDHJAI and RDH10: relationship with co-expression of nuclear receptors RARα and PPARβ/δ genes and some clinical characteristics in multiple myeloma].
    Kalitin NN; Chernykh YB; Buravtsova IV
    Vopr Onkol; 2016; 62(5):626-631. PubMed ID: 30695588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
    Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The flow-cytometric DNA content of the plasma cells of patients with multiple myeloma is a prognostic factor: a single institution experience.
    López-Otero A; Ruiz-Delgado GJ; Hernández-Arizpe A; Ruiz-Argüelles A; Ruiz-Argüelles GJ
    Hematology; 2010 Dec; 15(6):378-81. PubMed ID: 21114899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prognostic scoring system for patients with multiple myeloma classified as stage II with the Revised International Staging System.
    Jung SH; Kim K; Kim JS; Kim SJ; Cheong JW; Kim SJ; Ahn JS; Ahn SY; Yang DH; Kim HJ; Lee JJ
    Br J Haematol; 2018 Jun; 181(5):707-710. PubMed ID: 28466549
    [No Abstract]   [Full Text] [Related]  

  • 19. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.
    Bataille R; Robillard N; Avet-Loiseau H; Harousseau JL; Moreau P
    Haematologica; 2005 May; 90(5):706-7. PubMed ID: 15921396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma.
    Jost E; Gezer D; Wilop S; Suzuki H; Herman JG; Osieka R; Galm O
    Cancer Lett; 2009 Aug; 281(1):24-31. PubMed ID: 19299079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.